Venture Capital

Riverhead Capital Co-leads $186M Series B Round In Chinese Lepu Biotech – China Money Network

by chinamoneynetwork.com posted 12months ago 332 views
Chinese innovative biotech firm Lepu Biotech completed a nearly RMB1.291 billion(US$186 million) series B round of financing co-led by Riverhead Capital, Sunshine Insurance Group and Ping An Capital. SDIC Unity Capital, Haitong Innovation Capital Management and State New Central Enterprises Operating Investment Fund also participated in this round. Founded in 2018, Lepu Biotech is a Chinese biotech firm focusing on development of cancer diagnosis and therapy. The company, through its nine subsidiaries, has established a comprehensive industrial platform for target discovery, drug development, and drug production.